Clinical Trial Update: Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating a dendritic cell–based cancer vaccine in melanoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Melanoma, Tumor Vaccines | Phase 1 | Status: COMPLETED